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Vitamin D has well known effects on bone metabolism but there is increasing 
evidence for its role in immune regulation and cardiovascular risk.  Although 
vitamin D defiency is common in Australia and HIV populations in the 
developed world, epidemiological data surrounding 25-OH vitamin D levels 
(25(OH)D) and associated factors in Australian HIV patients is limited. 
 
A cross-sectional audit was conducted on 266 HIV positive patients in the 
Western Australian cohort looking at the prevalence of and co-variates 
relating to 25(OH)D deficiency. Log-transformed measures of 25(OH)D were 
analysed via linear regression modelling. 
 
Our studied cohort was predominantly male 209/266(79%) and on 
antiretroviral therapy (ART) 193/266(73%).  More than 30% of individuals had 
pigmented skin (6% Indigenous Australians, 11% African, 7% South-East 
Asian, 6% Indian and 3% other Asian/Melanesian).  200/266 patients (75%) 
had insufficient 25(OH) D levels (<75nmol/L) and 44/266 (17%) deficient 
25(OH)D levels (<30 nmol/L).  Consistent with published literature, 25(OH) D 
levels of pigmented patients were considerably lower than those of white 
Caucasians (mean reduction of 38%, p<0.0001).  Seasonal effects on 25(OH) 
D levels were also observed: compared with winter, measures obtained in 
spring were 4% higher (p=0.6), in summer 19% higher (p=0.07) and in 
autumn 34% higher (p=0.001).  Independent of pigmentation and season, 
neither current ART regimen (p=0.5) or duration or therapy (p=0.5) were 
associated with differing 25(OH) D levels (p=0.5). However, particular 
treatment effects noted included current tenofovir-containing ART (associated 
with 21% increase in 25(OH) D, p=0.01) and current efavirenz-containing 
regimens (associated with 19% decrease in 25(OH)  D levels, p=0.009).  
Although there was no association between 25(OH) D and BMI (p=0.4), lower 
25(OH)D levels were associated with higher fasting insulin (p=0.04) and 
fasting triglyceride levels (p=0.0002). 
 
Our study confirms the high prevalence of 25(OH)D deficiency in treated HIV 
patients and the expected strong effect of pigmented race and seasonality.  
Specific treatment effects observed that may arise from ART effects on 
vitamin D metabolism and the association between lower 25(OH)D and 
metabolic parameters warrant further investigation. 